TEAM-EPIC

Training Network for the Development of Bacterial ExoPolysaccharides for the treatment of Inflammatory Conditions

Coordinatore	SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS    more  Organization address address: Promenade 35 city: DAVOS PLATZ postcode: 7270 contact info Titolo: Dr. Nome: Liam Cognome: O'mahony Email: send email Telefono: +41 814100853 Fax: +41 814100840
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	1˙057˙931 €
EC contributo	1˙057˙931 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-12-01   -   2015-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS  Organization address address: Promenade 35 city: DAVOS PLATZ postcode: 7270 contact info Titolo: Dr. Nome: Liam Cognome: O'mahony Email: send email Telefono: +41 814100853 Fax: +41 814100840	CH (DAVOS PLATZ)	coordinator	270˙026.00
2	ALIMENTARY HEALTH LTD  Organization address address: KINSALE ROAD BUILDING 2800 CORK AIRPORT BUSINESS PARK city: "Passage West, Co. Cork" postcode: N/A contact info Titolo: Dr. Nome: Jennifer Cognome: Roper Email: send email Telefono: +353 21 4299104	IE ("Passage West, Co. Cork")	participant	317˙791.00
3	UNIVERSITAET FUER BODENKULTUR WIEN  Organization address address: Gregor Mendel Strasse 33 city: WIEN postcode: 1180 contact info Titolo: Prof. Nome: Friedrich Cognome: Altmann Email: send email Telefono: +43 1 47654 6062 Fax: +43 1 47654 6059	AT (WIEN)	participant	207˙192.00
4	ALIMENTARY HEALTH PHARMA DAVOS AG  Organization address address: OBERE STRASSE 22 city: DAVOS PLATZ postcode: 7270 contact info Titolo: Dr. Nome: Jennifer Cognome: Roper Email: send email Telefono: +353 85 7822399 Fax: +41 81 410 08 40	CH (DAVOS PLATZ)	participant	141˙863.00
5	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: O'connell Email: send email Telefono: 353215000000 Fax: 353215000000	IE (CORK)	participant	121˙059.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The essence of this proposal is to establish a collaborative training network which will develop novel immune-regulatory molecules from Bifidobacterium infantis 35624, for treatment of inflammatory diseases. A multidisciplinary team of four prestigious European partners has been assembled (SME & Coordinator - Alimentary Health Ltd (expert in developing probiotic products); Swiss Institute for Asthma and Allergy Research, (expert in immune-regulation); Vienna Institute of Biotechnology at Universität für Bodenkultur (expert in glycobiology); and University College Cork, Alimentary Pharmabiotics Centre and Department of Microbiology (expert in bioinformatics and glycobiology assembly in probiotic bacteria). Each partner will provide unique critical expertise, through knowledge, personnel and facilities which will be complementary and additive and will provide the synergistic expertise required to successfully deliver on the goal of this project and forge a long-lasting relationship. The end result: a unique opportunity for cross-sector state-of-the-art knowledge transfer and dissemination, through the identification of molecules from B. infantis 35624 with proven efficacy in the treatment of IBS and other inflammatory conditions – expected to have major commercialization, economic and health implications. B. infantis 35624 is a commensal micro-organism, originally isolated from human gastrointestinal tissue, which has demonstrated unique properties in human clinical studies. B. infantis 35624 consumption is associated with significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies. No other bacterial strain has shown significant improvement in Irritable Bowel Syndrome (IBS) symptoms. The exact mechanisms underpinning the clinical benefit are not known but modulation of the host immune response is strongly believed to play a role.'

Introduzione (Teaser)

As intriguing as it may sound, bacteria could have beneficial effects on our health. With this in mind, a European study is working to develop novel therapies based on bacterial components.